国产成人嫩模一区二区|超级黄色网页|兔子先生tz|麻豆文化传媒网站官网污|在线播放欧美日韩精品|爱豆影视传媒免费下载|蜜桃影像传媒av剧情|麻豆文化传媒APP最新iOS|陈可心倩女幽魂爱豆传媒|91国视频产,国产传媒播放,想看三级片,网红吃瓜黑料爆料网反差

Lab Leader: Liang Zhu

Lab Name:Laboratory of Cancer Pharmacology and Metabolomics

Lab Info：The lack of new drug targets for molecularly-targeted therapy and immunotherapy and the emergence of resistance are bottlenecks in cancer science and clinical practice. We pursue an exploration of the mechanisms of tumor initiation, progression and therapy resistance, from a new angle, using the team-built metabolomics-based integrated multiomics analysis. By this strategy, we aim to discover novel therapeutic targets and therapy resistance-overcoming targets, as well as to the research and development of new anticancer drugs. The findings have been published in top science journals such as Science Translational Medicine and Cell Metabolism and undergone the translational process.

Lab Members:

Lab Leader: Hao Wang

Lab Name:Laboratory of New Pathogenesis and New Drug Research of Neurodegenerative Diseases

Lab Info：Prof. Hao Wang’s research group relies on pharmacy discipline of Shanghai Jiaotong University School of Medicine, the construction discipline of national "double first-class" and "high-level local universities" in Shanghai. At present, there are one Professor, two associate professors, one experimenter, one postdoctoral and five graduate students in the group. Over the past twenty years, the research group has focused on the new pathogenesis of neurodegenerative diseases, new targets for intervention and new drug research and development. It has successively undertaken one National Key Basic Research Program of China (973 Plan), one National Science and Technology Major Project of "new drug creation and development", twelve National Natural Science Foundation Projects and three key projects of Shanghai Science and Technology Commission. It has published more than 60 papers in high-level magazines such as Cell Death & Differentiation, Advanced Science and Aging Cell, and has obtained more than 10 invention patents. The achievements won the first prize of the science and technology progress award of the Ministry of education, the second prize of the natural science award of the Ministry of Education, the second prize of the Chinese medical science and technology award, etc. Professor Wang Hao, the Principal Investigator, has served as the director of Chinese society of Pharmacology, director of Shanghai Pharmaceutical Association and vice chairman of the special committee of pharmacology, won the woman pace-setter of Shanghai education system, Shangyao Xinglin talent cultivation award, and trained five doctoral students and eight master's students, and four of them won national scholarships.

Lab Members:

Lab Leader: Zhou, B.-B.

Lab Name: Laboratory of Cancer Drug Resistance and Genetic Instability

Lab Info：Drug resistance and tumor relapse team mainly uses systems biology approaches (integrated genomics, cellular and molecular biology, biochemistry and animal models) to study the molecular mechanism of pediatric leukemia drug resistance and tumor relapse for both basic and translational intents. The team currently consists of 1 CO-PI, 5 research technicians, 2 postdoctoral fellows and 5 PhD candidates. Three previous postdoctoral fellows had been appointed as associate and assistant professor respectively. Three PhD graduates are engaged in post-doctoral trainings in the United States and China respectively.

Main research areas:

1. Basic mechanism and translational application of drug-resistant and tumor relapse in childhood leukemia.

2. Role of DNA damage response (DDR) in drug-resistant and tumor relapse of childhood leukemia.

3. Drug and tumor metabolism in drug-resistant and tumor relapse of childhood leukemia

Lab Members:

Lab Leader: Chao Fang

Lab Name: Laboratory of Smart Drug Delivery

Lab Info：Our research group is committed to developing smart drug delivery systems for efficient and low-toxic targeted therapy of malignant tumors. In the past five years, in the field of co-delivery systems for anticancer drugs, our research group has focused on the controllable optimization of pharmacokinetic profiles and created a series of new methods, new strategies and new technologies for the innovative construction of efficient co-delivery systems. Research results have been published in international journals such as Nat Commun, Adv Mater, Adv Sci, Adv Funct Mater, ACS Nano, Nano Lett. Some achievements are in clinical translation.

Lab Members:

Lab Leader: Xiaoling Gao

Lab Name: Laboratory of Brain Targeted Drug Delivery

Lab Info：Her group has been focusing on the creation of natural and biomimetic nanocarriers for achieving efficient and precise brain-targeted delivery of biomacromolecule medicines. The major work include: the development of lipoprotein biomimetic nanocarrier with multi-mode drug loading capacity and tunable targeting property; the disclosure of the pathway and mechanism for brain clearance of nanocarriers; and the applications of nanotherapeutics for the management of brain diseases. Her group has published over 60 articles in high-impact journals such as Nature Communications, Adv Science, ACS Nano, Nano Lett, and J Control Release, among others. Their work has been acknowledged and featured in Sci Transl Med, ACS Nano, and other journals, as well as in well-known professional media outlets. Her group had applied and gotten approved more than 20 innovation patents.

Lab Members:

Lab Leader: Peng Zhang

Lab Name: Laboratory of Synaptic Regulation

Lab Info：The human brain is made up of billions of neurons, which in turn communicate information with other neurons through trillions of synapses. Synapses are the basic structure of neuronal communication, synaptic plasticity and its precise regulation play an important role in various brain activities, including cognition, perception, decision making and sleep/awake balances. Whereas synaptic abnormalities or disorders are often accompanied by the occurrence of various brain diseases, such as Alzheimer's disease, autism, depression, etc. At present, our research group mainly focuses on the synaptic regulation to understand the pathogenesis of neurodegenerative diseases and psychiatric disorders. Research is carried out mainly from the following three directions:

1) Develop and optimize new tools for brain science research, namely new genetically encoded neurotransmitter fluorescent probes;

2) Explore the regulatory mechanism of synaptic transmission with multi-channel whole-cell patch clamp recording technique;

3) Understand the molecular and cellular mechanisms of synaptic regulation in Alzheimer's disease (AD) and autism spectrum disorders (ASDs).

Lab Members:

Lab Leader: Liang Zhang

Lab Name: Laboratory of Chemical Biology

Lab Info：The research field of my lab spans a broad range of chemical biology, structure biology, epigenetics and drug discovery. We are interested in studying the dynamic catalytic and regulation mechanisms of chemical modifications on biological macromolecules involved in Fatty acid biosynthesis, Nucleoside biosynthesis, and DNA/RNA methylation/demethylation pathways. These processes are vital for all living cells, and the biofunctions of enzymes involved in these processes are restrictively regulated spatio-temporally through chemical modifications. Our researches focus on elucidating the mechanisms of the key enzymes in adding, reading and removing the chemical modifications on the biological macromolecules, as well as the subsequent corresponding biological effects. We are also establishing efficient high throughput drug screening systems for novel leading drug compounds discovery against these potential drug targets. So far, our lab has published several research articles on Nature Chemical Biology, Nature Communications, Cell Research, PNAS, Chemical Science, Elife, etc, and obtained 2 national patents and applied a domestic patent.  Our works are supported by numerous grants such as the National Science Fund for Excellent Young Scholars, the Major Research Plan and General Program Research Plan of National Natural Science Foundation of China, Shanghai Shuguang Scholar program, Oriental Scholar of Shanghai College, and Shanghai Biomedical science and technology innovation program, etc.

Lab Members:

Lab Leader: Ying Shen

Lab Name: Laboratory of Anti-tumor Pharmacology

Lab Info：We mainly focus on the effect of tumor metabolic enzymes on EGFR inhibitors resistance and tumor metastasis in lung cancer. Our studies reveal several important original findings related to new tumor metabolic targets and First-in-Class drug candidates with potential clinical translation value. For example, she has identified a novel allosteric inhibitor of PGAM1, which allosterically blocks the structure of PGAM1, impacting both its catalytic activity and protein-protein interaction. PHGDH, ALDH1A1 and AKR1B1 have been revealed to promote lung cancer drug resistance via regulating cellular redox homeostasis. Relevant works have been published in high-rank SCI journals such as Cell Metabolism and Science Translational Medicine, and have applied five patents (3 of them have been already authorized). The cooperation potent have signed a transformation cooperation agreement.

Lab Members:

Lab Leader: Zeyu Xiao

Lab Name: Laboratory of Visualized Drug Delivery

Lab Info：Our group has been dedicated to develop visualized drug delivery systems with high sensitivity and high selectivity for disease diagnosis and therapy, by using interdisciplinary technologies and methods (e.g. chemistry, biology, pharmacology and molecular imaging). The specific research contents are as follows: (1) Developing visualized drug delivery systems based on in-vivo optical imaging (such as Raman imaging) or nuclear medical imaging technologies, for intra-operative diagnosis and removal of residual micro-tumors, reversing targeted-drug resistance, medication guidance and treatment evaluation; (2) Investigating oral drug delivery system for naked-eye visualization and treatment of colon diseases at the early stage; (3) Designing DNA-modularied programmable bivalent drugs for precise receptor regulation. Recently, we have published more than 40 research articles in the international academic journals (e.g. Chem Soc. Rev., Nature Comm. Angew. Chem., Nano Lett, ACS Nano, Adv Funct Mater., etc), and three Book Chapters. Among them, there has been 1 article cited more than 1000 times, 5 articles cited more than 200 times, 7 articles cited more than 100 times, and 3 articles selected as the highly cited papers by ESI. One visualized drug delivery system has begun clinical trial stage. In addition, we also have applied/authorized two international patents and one domestic patent.

Lab Members: